Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial

被引：0
|
作者：
Jeremy Pettus
Schafer C. Boeder
Mark P. Christiansen
Douglas S. Denham
Timothy S. Bailey
Halis K. Akturk
Leslie J. Klaff
Julio Rosenstock
Mickie H. M. Cheng
Bruce W. Bode
Edgar D. Bautista
Ren Xu
Hai Yan
Dung Thai
Satish K. Garg
Samuel Klein
机构：
[1] University of California San Diego,Division of Endocrinology
[2] Diablo Clinical Research,Barbara Davis Center for Diabetes
[3] Clinical Trials of Texas,Center for Human Nutrition
[4] AMCR Institute,undefined
[5] University of Colorado Anschutz Campus,undefined
[6] Rainier Clinical Research Center,undefined
[7] Dallas Diabetes Research Center,undefined
[8] Marin Endocrine Care and Research,undefined
[9] Atlanta Diabetes Associates,undefined
[10] REMD Biotherapeutics,undefined
[11] Washington University School of Medicine,undefined
[12] St. Louis,undefined
[13] MO and Sansum Diabetes Research Institute,undefined
来源：
Nature Medicine | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2959 / 2959
相关论文
共 50 条
  • [1] Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial
    Jeremy Pettus
    Schafer C. Boeder
    Mark P. Christiansen
    Douglas S. Denham
    Timothy S. Bailey
    Halis K. Akturk
    Leslie J. Klaff
    Julio Rosenstock
    Mickie H. M. Cheng
    Bruce W. Bode
    Edgar D. Bautista
    Ren Xu
    Hai Yan
    Dung Thai
    Satish K. Garg
    Samuel Klein
    Nature Medicine, 2022, 28 : 2092 - 2099
  • [2] Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial
    Pettus, Jeremy
    Boeder, Schafer C.
    Christiansen, Mark P.
    Denham, Douglas S.
    Bailey, Timothy S.
    Akturk, Halis K.
    Klaff, Leslie J.
    Rosenstock, Julio
    Cheng, Mickie H. M.
    Bode, Bruce W.
    Bautista, Edgar D.
    Xu, Ren
    Yan, Hai
    Thai Dung
    Garg, Satish K.
    Klein, Samuel
    NATURE MEDICINE, 2022, 28 (10) : 2092 - +
  • [3] Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial (vol 28, pg 2092, 2022)
    Pettus, Jeremy
    Boeder, Schafer C.
    Christiansen, Mark P.
    Denham, Douglas S.
    Bailey, Timothy S.
    Akturk, Halis K.
    Klaff, Leslie J.
    Rosenstock, Julio
    Cheng, Mickie H. M.
    Bode, Bruce W.
    Bautista, Edgar D.
    Xu, Ren
    Yan, Hai
    Thai, Dung
    Garg, Satish K.
    Klein, Samuel
    NATURE MEDICINE, 2023, 29 (11) : 2959 - 2959
  • [4] Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Pettus, Jeremy
    Boeder, Schafer C.
    Christiansen, Mark P.
    Denham, Douglas S.
    Bailey, Timothy S.
    Akturk, Halis K.
    Klaff, Leslie J.
    Rosenstock, Julio
    Cheng, Mickie H. M.
    Bode, Bruce W.
    Bautista, Edgar D.
    Yan, Hai
    Thai, Dung
    Garg, Satish K.
    Klein, Samuel
    DIABETES, 2021, 70
  • [5] Yogliptin monotherapy in type 2 diabetes: A 12-week randomized, double-blind, placebo-controlled phase II study
    Wang, Xin
    Wang, Ying
    Yong, Xiaolan
    Wu, Bojun
    Sun, Zilin
    Lou, Ning
    Wen, Qing
    Zhang, Yufang
    Li, Shiyun
    Li, Jiarui
    He, Yan
    Cheng, Jinluo
    Zhong, Xiangdong
    Shen, Jing
    Yang, Wenying
    JOURNAL OF DIABETES, 2022, 14 (12) : 822 - 830
  • [6] Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial
    Kadowaki, Takashi
    Haneda, Masakazu
    Inagaki, Nobuya
    Terauchi, Yasuo
    Taniguchi, Atsushi
    Koiwai, Kazuki
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    ADVANCES IN THERAPY, 2014, 31 (06) : 621 - 638
  • [7] Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial
    Takashi Kadowaki
    Masakazu Haneda
    Nobuya Inagaki
    Yasuo Terauchi
    Atsushi Taniguchi
    Kazuki Koiwai
    Henning Rattunde
    Hans J. Woerle
    Uli C. Broedl
    Advances in Therapy, 2014, 31 : 621 - 638
  • [8] The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial
    Najafipour, Mostafa
    Najafipour, Farzad
    Ostadrahimi, Alireza
    Ghavami, Maryam
    Razaghi, Zohreh
    Tutunchi, Helda
    Alamdari, Naimeh Mesri
    HEALTH PROMOTION PERSPECTIVES, 2024, 14 (04): : 380 - 387
  • [9] Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes
    van Bommel, E. J. M.
    Herrema, H.
    Davids, M.
    Kramer, M. H. H.
    Nieuwdorp, M.
    van Raalte, D. H.
    DIABETES & METABOLISM, 2020, 46 (02) : 164 - 168
  • [10] A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine
    Wang, Hsueh-Fang
    Liu, Wen -Chun
    Zailani, Halliru
    Chen, Ting-Bin
    Yang, Cheng-Chia
    Chang, Ching -Mao
    Tsai, I-Ju
    Yang, Chun-Pai
    Su, Kuan-Pin
    BRAIN BEHAVIOR AND IMMUNITY, 2024, 118 : 459 - 467
12345